Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.
Eli Lilly and Company announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed rival ...
It didn’t take long for the shine to come off one of biotech’s recent IPO success stories, with BioAge Labs scrapping a phase ...
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
As demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according to cybersecurity experts.
Novo Holdings’ $16.5 billion takeover of US contract development and manufacturing organisation (CDMO) Catalent does not ...
Lilly announces a $3B expansion in Wisconsin to boost production of weight loss drugs and strengthen its position in the ...
MIND Strongly Supporting Varoglutamstat’s Potential toImprove Kidney Function VIVA-MIND Phase 2 data confirm results of varoglutamstat’s benefit on eGFR in VIVIAD; Company now has two independent doub ...
Stock futures edged lower Monday morning as investors eye this week’s key inflation report. The Consumer Price Index (CPI) ...
The foreign ministry of Russia, a longtime ally, did not provide details on where President Bashar al-Assad had gone. Rebels stormed the Syrian capital on Sunday without encountering any ...
Jupiter at Opposition This Weekend: Here's the Best Time to See It ...